TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04514549

Intervention type: DEVICE
Intervention: Emerald
Description: The Emerald is a wireless sensor that can track the motion, breathing, and sleep of subjects without touching or requiring any interaction with the subjects, allowing them to go about their normal lives. The physical device is roughly a 30 x 35 x 5 cm box that contains directional antennas and a motherboard to process these signals. In typical operation, the device is mounted onto a wall within a clinic or home setting using peel-away (reversible) mount strips.
Study: NCT03921541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegzilarginase
Description: Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegzilarginase
Description: Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Study: NCT03965299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VERUM TTNS
Description: * Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM TTNS
Description: * Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase
Study: NCT03388788

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Positron Emission Tomography (PET) imaging for research.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Positron Emission Tomography (PET) imaging for research.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Study Protocol
Description: 5-day circadian study schedule

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Study Protocol
Description: 5-day circadian study schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Meta-Hydroxyephedrine (mHED)
Description: 11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Meta-Hydroxyephedrine (mHED)
Description: 11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-CGP12177
Description: Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-CGP12177
Description: Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O15-water
Description: Blood flow will be measured via PET imaging with infusion of O15-water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O15-water
Description: Blood flow will be measured via PET imaging with infusion of O15-water.
Study: NCT03506633

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each subject in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each subject in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured.
Study: NCT02506621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECHNOMED pocket ECG
Study: NCT03706352

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunneling epidural catheter
Description: The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tunneling epidural catheter
Description: The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.
Study: NCT00449969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoll AED pro
Description: Arm one (Extended feedback) offers full feedback guidance during CPR

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zoll AED pro
Description: In arm two (limited feedback) feedback is modified lacking several elements of feedback
Study: NCT00312962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT)
Description: TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer games
Description: The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
Study: NCT04029038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT04348578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QMix 2in1
Description: In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
Study: NCT01517776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
Study: NCT03012945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia
Description: Combined epidural-general anesthesia and postoperative epidural analgesia. General anesthesia is performed as that in the general anesthesia group. Epidural anesthesia is performed with ropivacaine. Epidural analgesia is performed with a mixture of ropivacaine and sufentanil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia and postoperative intravenous analgesia. General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance. Intravenous analgesia is performed with morphine.
Study: NCT04088357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TolaSure Topical Gel
Description: TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vehicle Gel
Description: TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
Study: NCT00268398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin, folinic acid, fluorouracil
Description: folinic acid 200 mg/m² (day 1\&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1\&2) continuous 5FU 600mg/m² (day 1 to 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, irinotecan, folinic acid, fluorouracil
Description: FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)
Study: NCT00504231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Influenza Vaccine (2007-2008)
Description: Manufactured by Sanofi Pasteur

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Influenza Vaccine (2007-2008)
Description: Manufactured by Sanofi Pasteur

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Influenza Vaccine (2007-2008)
Description: Manufactured by Sanofi Pasteur

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Influenza Vaccine (2007-2008)
Description: Manufactured by Sanofi Pasteur
Study: NCT02405208

Intervention type: DEVICE
Intervention: PyroTITAN HRA
Description: Humeral resurfacing using the PyroTITAN HRA device
Study: NCT02506621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZIO xt patch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoMe
Study: NCT03746756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study.
Study: NCT04484012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Description: Given IV
Study: NCT00836472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin 5 mg/500 mg Tablets
Description: 1 x 5 mg/500 mg, single-dose fasting
Study: NCT03746756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT+RMC-PC
Description: In addition to SBIRT, those randomly assigned to the experimental condition will also receive Recovery Management Checkups for Primary Care (RMC-PC) at the time of referral/study enrollment and quarterly for 12 months. RMC-PC involves a linkage manager reviewing the assessment data and using motivational interviewing to encourage the person to go to treatment and identify barriers to entering or staying in treatment. It also involves problem solving on how to address common issues (e.g., transportation, scheduling), staying in regular contact for the first two weeks to make sure they stay in treatment, and checking in on continuing care compliance at later checkups.
Study: NCT05800119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain-level condition
Description: Participants will receive a brief reading passage about the neurobiological effects of psychotherapy.
Study: NCT00836472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucovance® 5 mg/500 mg Tablets
Description: 1 x 5 mg/500 mg, single-dose fasting
Study: NCT04342663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
Study: NCT02977221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
Study: NCT01959204

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: Pain
Study: NCT05249595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electromypgraphy-based interface to predict human ankle joint motion intent and use in ankle assistive devices
Description: The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the sEMG signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
Study: NCT05800119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mind-level condition
Description: Participants will receive an active control consisting of a brief reading passage about the effectiveness of psychotherapy.
Study: NCT03314649

Intervention type: OTHER
Intervention: Observational study
Description: Lavage of the Peritoneal Cavity
Study: NCT00835484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir Capsules 300 mg
Description: 1 x 300 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMNICEF® 300 mg
Description: 1 x 300 mg, single-dose fasting
Study: NCT01621282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: A 6-month interactive course on critical appraisal

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Conventional
Description: Conventional method/no intervention
Study: NCT02826304

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy
Description: All the cases were performed by the same surgical team~1. Incision is made at the anterior cervical lip below the bladder reflection~2. Anterior peritoneal entry .~3. Douglas pouch entry.~4. The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~5. Uterine artery clamping division and ligation~6. After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~7. Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~8. Hemostasis~9. The vaginal vault is closed after insertion of intraperitoneal drain and

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic assisted vaginal hysterectomy
Description: 1. Uterine manipulator was inserted through the cervix to mobilize the uterus~2. Veress needle was inserted through the base of the umbilicus~3. creation of pneumoperitoneum~4. Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~5. The round and the utero-ovarian ligament are coagulated and divided.~6. Dissection through the vesico-uterine space to displace bladder away from the cervix.~7. Uterine artery was coagulated and divided laparoscopically~8. anterior colpotomy over the cup of the uterine elevator.~9. Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis.
Study: NCT02999893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
Study: NCT01591161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: 1 drop of study medication into the study eye QID for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 drop of vehicle into the study eye QID for 14 days.
Study: NCT05278923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SALAD simulation device
Description: An airway CPR manikin was modified to simulate regurgitation during CPR . A manual pump was fixed on the bottom of the torso to simulate the stomach. A clear vinyl tube was connected the manikin's oesophagus and the outflow port of the pump. A water container outside the manikin was filled with simulated gastric content and connected to the inflow port of the pump through another vinyl tube. The manikin's left main bronchus was occluded using a red cap provided by the manufacturer. The lung was simulated by an anaesthesia breathing bag placed outside the manikin and connected to the manikin's right main bronchus via a breathing circuit. A compression pad was attached to the bottom of the manikin's compression plate. During chest compression, the compression pad squeezed the pump to regurgitate gastric contents into the oropharynx
Study: NCT03931616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STEMO
Description: STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
Study: NCT01510938

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. acidophilus DDS-1, B. lactis UABLA-12
Description: 1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
Study: NCT03356691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary Spiritist Therapy
Description: Complementary Spiritist Therapy:~1. Prayer: for 1 to 2 minutes.~2. Spiritual education: reading and commentary of the Gospel according to Spiritism, about 7 minutes.~3. Spiritist passe, for 2-min.~4. Fluid therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Prayer
Description: Individuals will receive prayer during 1 to 2 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Spiritist passe
Description: Individuals will receive Spiritist passe during 5 to 10 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laying on of hands with intent to heal
Description: Individuals will receive laying on of hands with intent to heal during 5 to 10 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Fluid therapy.
Description: Individuals will receive fluid therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: No-fluid therapy.
Description: Individuals will receive no-fluid therapy.
Study: NCT02805764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Homeoblock
Description: A removable, functional dental appliance to be worn nightly for 1 year Pending 510(k) clearance for the use of reducing snoring and mild to moderate obstructive sleep apnea in adults. A class II medical device.
Study: NCT01946477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Study: NCT04149691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL304110
Description: CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
Study: NCT03639181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB226
Description: 3mg/kg treat every 2 weeks
Study: NCT03928704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
Study: NCT03526432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
Study: NCT00755677

Intervention type: OTHER
Group type: OTHER
Intervention: Pulses
Description: subjects consume 1 pulse food daily for eight weeks
Study: NCT02616484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate (DCA)
Description: Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr.
Study: NCT00868660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZP1848
Description: sc. bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP1848
Description: sc. bolus